ARTBIO Strengthens Leadership with Four New Board Members and Advisory Role for Co-Founder ARTBIO, a clinical-stage radiopharmaceutical company, has appointed four new board members and shifted its co-founder to an advisory role, aiming to enhance its alpha radioligand therapy programs.

ARTBIO Strengthens Leadership with Four New Board Members and Advisory Role for Co-Founder #United_States #Cambridge #ARTBIO #Alpha_Radioligand #Roy_Larsen

ARTBIO Secures $132 Million Series B Funding for Cancer Therapy Advancements ARTBIO has successfully closed a $132 million Series B financing round aimed at advancing its innovative alpha radioligand therapies and enhancing manufacturing capabilities.

ARTBIO Secures $132 Million Series B Funding for Cancer Therapy Advancements #USA #Cambridge #cancer_therapy #ARTBIO #Alpha_Radioligand

ARTBIO Secures $132 Million in Series B Financing for Cancer Treatment Advancements ARTBIO has successfully closed a $132 million Series B funding round to advance its pipeline of innovative cancer therapies and enhance its manufacturing capabilities.

ARTBIO Secures $132 Million in Series B Financing for Cancer Treatment Advancements #USA #Cambridge #cancer_therapy #ARTBIO #Alpha_Radioligand